Nordic EMBL Partnership for Molecular Medicine
FIMM is characterized first and foremost by its partnership with the flagship of European biosciences research, the European Molecular Biology Laboratory (EMBL). The Nordic EMBL Partnership for Molecular Medicine was established on 3 October 2007, and it involves sister institutions in Umeå in Sweden, Oslo in Norway and Aarhus in Denmark, each acting in their own areas of research.
In March 2013 the Nordic EMBL Partnership for Molecular Medicine celebrated two important milestones: the renewal of the partnership agreement for an extended period of 10 years, and the expansion of the Nordic EMBL network with the official opening of the Danish Research Institute of Translational Neuroscience (DANDRITE) at Aarhus University, which became its Danish node.
EMBL provided an organizational and administrative model, advice and a strong brand name for the launch and operation of FIMM. FIMM recruits promising principal investigators and PhD students globally according to the EMBL model. An important aspect for the future of EMBL collaboration is scientific and technological interaction. FIMM represents an important step for EMBL towards translational and medical research, and it is in the interest of both parties that links to medical research and biotechnology industry are enforced in Finland and in the EU.
Nordic EMBL Nordic Partnership for Molecular Medicine is based on the proven research strengths in Finland, which have created an initial focus for FIMM on three areas
- human genomics
- medical systems biology
- translational research
While all parties of the Nordic EMBL Partnership strive towards translational aims, FIMM is unique in its focus towards human genomics and medical systems biology.
Read more about the partnership:
Read more about the other Nordic nodes: